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Abstract
Introduction: Five different molecular subtypes of breast cancer have been identified through gene expression 
profiling. Each subtype has a characteristic expression pattern suggested to partly depend on cellular origin. We aimed 
to investigate whether the molecular subtypes also display distinct methylation profiles.
Methods: We analysed methylation status of 807 cancer-related genes in 189 fresh frozen primary breast tumours and 
four normal breast tissue samples using an array-based methylation assay.
Results: Unsupervised analysis revealed three groups of breast cancer with characteristic methylation patterns. The 
three groups were associated with the luminal A, luminal B and basal-like molecular subtypes of breast cancer, 
respectively, whereas cancers of the HER2-enriched and normal-like subtypes were distributed among the three 
groups. The methylation frequencies were significantly different between subtypes, with luminal B and basal-like 
tumours being most and least frequently methylated, respectively. Moreover, targets of the polycomb repressor 
complex in breast cancer and embryonic stem cells were more methylated in luminal B tumours than in other 
tumours. BRCA2-mutated tumours had a particularly high degree of methylation. Finally, by utilizing gene expression 
data, we observed that a large fraction of genes reported as having subtype-specific expression patterns might be 
regulated through methylation.
Conclusions: We have found that breast cancers of the basal-like, luminal A and luminal B molecular subtypes harbour 
specific methylation profiles. Our results suggest that methylation may play an important role in the development of 
breast cancers.
Introduction
Breast cancer is a complex and heterogeneous disease
and one of the leading causes of death among women.
Tumourigenesis is a multistep process resulting from the
accumulation of genetic alterations such as mutations,
rearrangements and copy number variations, but also
epigenetic alterations such as promoter methylation and
histone modification [1,2]. DNA methylation plays an
essential role in development, chromosomal stability, and
for maintaining gene expression states [1]. DNA methyla-
tion occurs when methyl groups are added to cytosines in
CpG dinucleotides, leading to a closed chromatin confor-
mation and gene silencing. CpGs are often found at
increased frequencies in promoter regions, forming CpG
islands. Hypermethylation of CpG islands affects genes
involved in cell cycle control, DNA repair, cell adhesion,
signal transduction, apoptosis and cell differentiation [1-
3]. In tumour cells, local promoter hypermethylation is
often accompanied by global hypomethylation [1]. This
results in more global patterns of methylation as com-
pared with mutation spectra, which differ greatly in
extent and patterns between tumours [4].
Gene silencing and maintenance of cellular identity can
also be mediated by histone modifications carried out by
polycomb group (PcG) proteins. Enhancer of zeste
homolog 2 (EZH2) is a core member of the polycomb
repressive complex 2 (PRC2) that catalyses the histone
mark characteristic for PcG-mediated silencing: trimeth-
ylation of lysine 27 on histone H3 (H3K27me3), which
leads to the blocking of transcriptional activation factors
and thereby gene silencing independent of promoter
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methylation [5]. Other members of the PRC2 complex
include suppressor of zeste 12 homolog (SUZ12) and
embryonic ectoderm development (EED) [6]. PRC2 tar-
get genes are involved in embryonic development, differ-
entiation and cell fate decisions [7]. PcG proteins are
thought to silence genes in a very dynamic fashion [8]. In
cancer cells, the presence of PRC2 can lead to recruit-
ment of DNA methyltransferases (DNMTs) resulting in
de novo DNA methylation and more permanent repres-
sion of PRC2 target genes [9]. Moreover, many of the
genes that undergo promoter methylation in cancer are
already expressed at low levels in corresponding normal
cells, suggesting that a large fraction of de novo methyla-
tion events in cancer cells are not subject to growth selec-
tion but instead reflect an instructive mechanism
inherent of the normal cell from which the tumour origi-
nated [10,11].
Several microarray studies have shown that breast
tumours can be divided into at least five molecular sub-
types based on gene expression profiles [12-14]. These
subtypes (basal-like, luminal A (lumA), luminal B (lumB),
human epidermal growth factor receptor 2 (HER2)-
enriched and normal-like) have been suggested to origi-
nate from different precursor cells and follow different
progression pathways. Herein, we investigated whether
the molecular subtypes show specific methylation pat-
terns by analysing a panel of 807 cancer-related genes in
189 breast tumours. We report that the breast cancer
subtypes, especially lumA, lumB and basal-like, demon-
strate different methylation profiles.
Materials and methods
Patients and tumours
Fresh frozen primary tumour tissue from 189 breast can-
cer patients, including 15 BRCA1 and 13 BRCA2 muta-
tion carriers, 43 non-BRCA1/2-familial (familial), 115
sporadic and 3 cases with unknown family status, were
obtained from the Southern Sweden Breast Cancer
Group's tissue bank at the Department of Oncology at
Skåne University Hospital in Sweden. All tumours were
macrodissected and evaluated for tumour cell content by
an experienced pathologist. Moreover, the majority (168/
189) of samples were analysed by array comparative
genomic hybridization (aCGH) and found to display
genomic profiles with aberrations consistent with the
presence of a large fraction of tumour cells. Normal
breast tissue from four breast cancer patients was also
included. Patient and tumour characteristics are shown in
Table 1. The study was approved by the regional ethical
committee at Lund University (reg. no. LU240-01 and
2009/658), waiving the requirement for informed consent
for the study.
DNA isolation
Genomic DNA was isolated from fresh frozen primary
breast tumours in a three-step procedure. Tumour cells
were pre-treated with proteinase K (20 mg/ml) at 55°C
over-night, DNA was purified using the Promega Wizard
Genomic DNA Purification kit (Promega Corporation,
Madison, WI, USA) and finally DNA was further purified
by phenol/chloroform treatment in phase-lock tubes.
DNA was quantified using a NanoDrop (ThermoScien-
tific, Wilmington, DE, USA).
Methylation analysis
Bisulfite conversion of 500 ng genomic DNA was per-
formed using the EZ DNA Methylation kit (Zymo
Research, Orange, CA, USA) following the manufac-
turer's protocols. Methylation analysis was performed
using Illumina GoldenGate Methylation Cancer Panel I
(Illumina, San Diego, CA, USA) [15]. In this panel 1,505
CpG loci corresponding to 807 cancer-related genes are
analysed simultaneously. Primers designed to match
either the methylated or unmethylated state of a CpG site
are hybridised to bisulfite-converted DNA. After an
extension and ligation step the templates are amplified
using two different fluorescently labelled universal prim-
ers, one for each methylation state, and then hybridised
to corresponding sequences on an array. For each CpG
site, methylation status is essentially calculated as the
ratio of fluorescence from the methylated state over the
sum of fluorescence from the methylated and unmethy-
lated states, and presented as a β-value [15]. The β-values
are continuous values between 0 and 1, with 0 corre-
sponding to completely unmethylated sites and 1 to com-
pletely methylated sites. The methylation data have been
deposited in NCBI's Gene Expression Omnibus (GEO)
[16,17] and are accessible through GEO Series accession
number [GEO:GSE22210].
Gene expression and DNA copy number data sets
The majority of the tumours (179/189) are part of a larger
set (n = 577) with gene expression data obtained using
oligonucleotide arrays (GEO Platform GPL5345) pro-
duced at the SCIBLU Genomics Centre at Lund Univer-
sity, Sweden [18] as described by Jönsson et al. [19] and
processed as described [20]. Briefly, expression levels
have been centred across all 577 samples to obtain
expression levels relative to a large set of breast tumours.
Also, samples have been classified into molecular sub-
types according to the gene expression centroids pub-
lished by Hu et al. [14] as described [21], with samples
having Pearson correlations smaller than 0.2 to all cen-
troids considered to be non-classified. Relative expres-
sion levels for all 511 oligonucleotide probes for genes
with CpG sites on our methylation assays are available in
Additional File 1. For analysis of expression of EZH2 and
PRC2 targets, we used all 286 (of 577) tumours that were
primary tumours, Swedish, and classified into a subtype
[see Additional File 2]. For 168 of 189 tumours, aCGH
d a t a  w e r e  a v a i l a b l e  a s  p a r t  o f  a n o t h e r  s t u d y  [ 2 0 ] .  F o r
aCGH, BAC arrays with more than 32,000 clones (GEOH
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Table 1: Patient and tumour characteristics for the 189 patients
Characteristic Basal-like
(n = 43)
(%)
LumA
(n = 46)
(%)
LumB
(n = 35)
(%)
HER2-enriched
(n = 14)
(%)
Normal-like
(n = 17)
(%)
Non-classified
(n = 24)
(%)
Non-GEX
(n = 10)
(%)
Total
(n = 189)
(%)
Family status
BRCA1 9 (21) 1 (2) 1 (3) 0 1 (6) 0 3 (43) 15 (8)
BRCA2 1 (2) 1 (2) 7 (20) 0 0 0 4 (57) 13 (7)
Familial 7 (16) 10 (22) 11 (31) 3 (21) 5 (29) 7 (29) 0 43 (23)
Sporadic 26 (60) 34 (74) 16 (46) 11 (79) 11 (65) 17 (71) 0 115 (62)
Unknown 0 0 0 0 0 0 3 3
ER status
Positive 2 (5) 44 (96) 31 (91) 5 (36) 10 (67) 20 (83) 1 (100) 113 (65)
Negative 38 (95) 2 (4) 3 (9) 9 (64) 5 (33) 4 (17) 0 61 (35)
Unknown 3 0 1 0 2 0 9 15
PgR status
Positive 2 (5) 44 (96) 28 (82) 5 (36) 8 (53) 20 (83) 1 (100) 108 (62)
Negative 38 (95) 2 (4) 6 (18) 9 (64) 7 (47) 4 (17) 0 66 (38)
Unknown 3 0 1 0 2 0 9 15
Histological grade
Grade 1 0 9 (28) 3 (10) 0 1 (8) 5 (23) 0 18 (12)
Grade 2 2 (5) 20 (63) 10 (34) 3 (27) 8 (62) 5 (23) 0 48 (32)
Grade 3 39 (95) 3 (9) 16 (55) 8 (73) 4 (31) 12 (54) 0 82 (55)
Unknown 2 14 6 3 4 2 10 41
Node status
Negative 28 (68) 36 (80) 17 (61) 11 (85) 9 (56) 16 (70) 0 117 (70)
Positive 13 (32) 9 (20) 11 (39) 2 (15) 7 (44) 7 (30) 0 49 (30)
Unknown 2 1 7 1 1 1 10 23
Age (median) 46 49.5 48 45.5 49 48.5 na 48
Cases for which data are unknown are excluded from total when calculating percentage.
ER, oestrogen receptor; GEX, gene expression; HER2, human epidermal growth factor receptor 2; lumA, luminal A; lumB, luminal B; na, not available; PgR, progesterone receptor.Holm et al. Breast Cancer Research 2010, 12:R36
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Platform GPL4723) were produced at the SCIBLU
Genomics Centre at Lund University, Sweden [18] as
described [19], and analysed as described [22]. Gain of
EZH2 and the fraction of genome altered were calculated
as described [23] [see Additional File 3].
Data analysis
The Beadstudio Methylation Module (Illumina, San
Diego, CA, USA) was used for data extraction, normalisa-
tion and quality control. β-values for all 1,452 CpG sites
(corresponding to 803 genes) that passed Beadstudio
quality control are available for all 189 tumours and 4
normal samples [see Additional File 4]. β-values were
stratified into three groups, all values 0.3 or below were
set to 0, values above 0.3 and below 0.7 were set to 0.5,
and finally values 0.7 and above were set to 1 and inter-
preted as hypermethylated. Methylation frequencies for
s a m p l e s  w e r e  c a l c u l a t e d  a s  t h e  f r a c t i o n  o f  C p G s  w i t h
value 1. Stratified data were used for all subsequent analy-
s e s .  S t r a t i f i e d  β - v a l u e s  w e r e  m e a n - c e n t r e d  a c r o s s  a l l
tumours to generate relative methylation levels. Relative
methylation levels for all 189 tumours and 1,452 CpG
sites are available in Additional File 5.
Clustering analyses were performed in MultiExperi-
ment Viewer (MeV) [24] using relative methylation levels
and the most variable CpG sites by excluding those with a
standard deviation less than 0.3 across samples. Hierar-
chical clustering was performed using Pearson correla-
tion distance and average linkage. K-means clustering
was performed using Pearson correlation distance. Asso-
ciations between subtypes and clusters were assessed
using Fisher's exact test in R [25] on 2 × 2 contingency
tables for the 179 tumours with expression data. Differen-
tially methylated CpGs were identified using analysis of
variance (ANOVA) with five groups, 1,000 permutations,
and a false significant number of 10 or less (correspond-
ing to false discovery rate (FDR) < 1%) in MeV. Signifi-
c a n c e  a n a l y s i s  o f  m i c r o a r r a y s  ( S A M )  [ 2 6 ]  w i t h  1 , 0 0 0
permutations and FDR of 0% was used in MeV to identify
significant CpGs for each subtype, using two-class com-
parisons between tumour samples belonging to a subtype
and all other tumour samples. Survival analysis was per-
formed in R using the survival package. For each CpG
site, the correlation between expression and methylation
was calculated and the global association was assessed
using a binomial test for the number of negative correla-
tion coefficients. Fisher's exact test, binomial test, t-test,
ANOVA and Wilcoxon test were performed in R. All
tests were two-sided.
Following Ben-Porath et al. [27] we used a gene set for
PRC2 targets consisting of the 654 genes identified by Lee
et al. [28] using chromatin immunoprecipitation (ChIP)
arrays as bound by all of SUZ12, EED, and H3K27me3 in
human embryonic stem (ES) cells. To explore genes
under PRC2 control in breast tumour cells, we used three
gene sets: (i) 853 genes identified by Gupta et al. [29]
using ChIP arrays as being occupied by EZH2, SUZ12
and H3K27me3 after HOTAIR  overexpression in the
oestrogen receptor (ER)-negative breast cancer cell line
MDA-MB-231, (ii) the top 600 promoters (mapped to
451 genes) identified by Squazzo et al. [30] using ChIP
arrays as being occupied by SUZ12 in the ER-positive
breast cancer cell line MCF7, and (iii) 44 genes identified
by Tan et al. [31] using RNA interference, expression
arrays and ChIP studies as being selectively repressed by
PRC2 in MCF7. For each tumour, we calculated the aver-
age relative methylation of a gene set as the average of the
relative methylation levels of all CpG sites matching a
gene in the gene set. Similarly, we calculated the average
relative expression of a gene set as the average of the
expression levels for all genes in the gene set.
Results
Unsupervised clustering reveals molecular subtype-
specific methylation patterns
Hypermethylation was observed in all 189 breast
tumours, on average affecting 31% of all analysed CpG
sites. Unsupervised hierarchical clustering using the 332
most variably methylated CpG loci, corresponding to 247
genes, divided the tumours into three main branches
(Figure 1a) [see Additional File 6]. The division into the
two main branches is mainly dependent on ER status (P =
2 × 10-13, Fisher's exact test). The branch with predomi-
nantly ER-negative tumours is associated with the basal-
like subtype (P = 6 × 10-22). The second division splits the
predominantly ER-positive luminal tumours into two
clusters, one associated with lumA tumours (P = 0.0004),
and another containing a mixture of all subtypes, but
including the majority of lumB (P = 0.0002) and HER2-
enriched (P = 0.03) tumours. Normal-like tumours are
found in all clusters. Survival analysis demonstrated
expected results with best outcome in the lumA-associ-
ated cluster and worst outcome in the basal-like-associ-
ated cluster (P = 0.05, log-rank test; Figure 1b) [13,14].
Additionally, for the samples with aCGH data (169/189)
we investigated the fractions of the genome altered, rep-
resenting the percentage of BAC clones subjected to gain
or loss for each sample. We found larger fractions altered
in tumours in the basal-like-associated Cluster 3 and
smaller fractions in tumours of the lumA-associated
Cluster 2 (P = 4 × 10-14, ANOVA; Figure 1c) corroborat-
ing earlier findings by Hu et al. [32]. We used S-phase
fraction as a measure of cellular proliferation of tumours
to further delineate the differences between the clusters.
The clusters contained tumours with significantly differ-
ent S-phase fractions (P = 4 × 10-9, ANOVA; Figure 1d).
As expected, tumours in the basal-like-associated cluster
had the highest S-phase fractions, and tumours in theHolm et al. Breast Cancer Research 2010, 12:R36
http://breast-cancer-research.com/content/12/3/R36
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lumB-associated cluster had higher S-phase fractions
than tumours in the lumA-associated cluster.
To investigate the robustness of the results from the
hierarchical clustering, K-means clustering was per-
formed varying the number of clusters (K) from two to
five [see Additional File 7]. For a K of 2, we found one
cluster associated with lumA (P = 6 × 10-4, Fisher's exact
test) and lumB (P = 6 × 10-9) tumours and one cluster
associated with basal-like tumours (P = 5 × 10-14). For a K
of 3, we found, as for the hierarchical clustering, that the
three clusters were significantly associated with lumA (P
= 3 × 10-6), lumB (P = 4 × 10-5) and basal-like (P = 2 × 10-
26) tumours, respectively. For a K of 4, we again found
three clusters associated with lumA (P = 2 × 10-6), lumB
(P  = 2 × 10-6) and basal-like (P  = 3 × 10-20) tumours,
respectively, whereas the remaining cluster was the small-
est (11% of tumours) and contained a mixture of sub-
types. For a K of 5, two clusters were associated with
lumA tumours (P = 0.001 and P = 0.01, respectively), one
cluster with lumB tumours (P = 1 × 10-7), one cluster with
basal-like tumours (P = 8 × 10-25), whereas the remaining
cluster again was the smallest (12% of tumours) and con-
tained a mixture of subtypes. For smaller K, normal-like
tumours were found in most clusters, but for a K of 5, 13
of 17 normal-like tumours were in the two lumA-associ-
ated clusters (P  = 0.01). However, HER2-enriched
Figure 1 Unsupervised clustering of 189 tumours based on the 332 most variably methylated CpGs. (a) Hierarchical clustering. The heatmap 
shows relative methylation levels (red, more methylated; green, less methylated). Clustering results in three clusters associated with lumB, lumA and 
basal-like tumours, respectively. (b) Kaplan-Meier demonstrating longest survival in lumA-associated Cluster 2 and shortest in basal-like-associated 
Cluster 3. P-value was calculated using log-rank test. (c) Fraction of genome altered (FGA) highest in basal-like-associated Cluster 3 and lowest in lumA-
associated Cluster 2. P-value was calculated using analysis of variance (ANOVA). (d) S-phase fraction highest in basal-like-associated Cluster 3 and low-
est in lumA-associated Cluster 2. P-value was calculated using ANOVA. The number of tumours in each subtype is shown at top.
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tumours were for all K present in all clusters. In sum-
mary, based on the investigated panel of CpGs, the meth-
ylation pattern of basal-like tumours clearly differs from
that of other subtypes and a group dominated by lumB
tumours appears to be more frequently methylated (Fig-
ure 1a).
Array-based methylation analysis corroborates individual 
CpG sites associated with clinical parameters
To validate the performance of our methylation assay, we
investigated the relative methylation levels of genes previ-
ously reported as having methylation patterns associated
with ER and HER2 status in breast tumours. Sunami et al.
investigated methylation of eight tumour-related genes in
breast tumours using methylation-specific PCR and cap-
illary-array electrophoresis analysis, and identified
RASSF1, GSTP1 and APC as having significantly lower
methylation frequencies in tumours that were ER-nega-
tive and HER2-negative (double negative) compared with
tumours that were either ER-positive or HER2-positive
[33]. Seven CpG sites for these three genes were present
on our array (Table 2). In concordance with the results by
Sunami et al., we found the methylation levels of all these
seven CpG sites to be significantly lower in the basal-like
subtype (corresponding to their group of double-negative
tumours) compared with the luminal or HER2-enriched
subtypes (corresponding to their ER-positive or HER2-
positive tumours; Table 2). Moreover, we found all CpG
sites for RASSF1 and APC, but none for GSTP1, to have
significantly higher methylation levels in ER-positive than
in ER-negative tumours (Table 2). We conclude that our
assay recapitulates findings by others using a different
method in independent tumours. Also, the accuracy and
reproducibility of the platform have been thoroughly vali-
dated elsewhere [15,34,35].
Methylation status correlates with gene expression
Next, we studied correlations between methylation status
and gene expression. All CpG sites for which we had
methylation data were matched based on gene symbols to
available gene expression data, and methylation levels
w e r e  c o r r e l a t e d  w i t h  g e n e  e x p r e s s i o n  l e v e l s  a c r o s s
tumour samples. This approach identified 470 unique
genes represented by 832 CpG sites and by 511 oligonu-
cleotide probes on the expression arrays. In total there
were 906 pairs of CpG sites and oligonucleotide probes
with the same gene symbol for both platforms [see Addi-
tional File 8]. For 113 of these 906 methylation-expres-
sion pairs, the relative methylation level of the CpG site
did not change across the tumours. A highly significant
fraction (569 pairs, 72%) of the remaining 793 expression-
methylation pairs with varying relative methylation levels
showed inverse correlation between relative methylation
levels and expression levels (P = 2 × 10-35, binomial test).
Thus, we found an inverse correlation between methyla-
tion and gene expression for a similar fraction of CpG
sites as has previously been found for follicular lym-
phoma using the same methylation assay [35].
High methylation frequency among luminal B tumours
To further study variations in methylation frequencies we
used ANOVA to identify 196 CpGs (corresponding to
163 genes) with methylation patterns associated with the
molecular subtypes [see Additional File 9]. Methylation
frequencies for these CpGs were calculated for molecular
subtype, family status, hormone receptor status, histolog-
ical grade, node status, age, tumour size and tissue (Table
3). The methylation frequency of these CpGs was signifi-
cantly different between the molecular subtypes (P = 2 ×
10-7, ANOVA). The CpGs were in particular found to be
more frequently methylated in lumB tumours and less
Table 2: Average relative methylation levels of genes previously associated with ER and HER2 status
CpG site Basal-like
(n = 43)
Luminal or HER2-enriched
(n = 95)
P-value1 ER-
negative
(n = 61)
ER-
positive
(n = 113)
P-value1
RASSF1_E116_F -0.37 0.16 2 × 10-11 -0.22 0.13 2 × 10-7
RASSF1_P244_F -0.32 0.16 2 × 10-11 -0.19 0.12 3 × 10-7
GSTP1_E322_R -0.24 0.07 2 × 10-5 -0.02 0.03 0.4
GSTP1_P74_F -0.11 0.03 0.02 -0.04 0.03 0.2
GSTP1_seq_38_S
153_R
-0.10 0.05 6 × 10-3 -0.01 0.02 0.7
APC_P14_F -0.38 0.11 2 × 10-8 -0.19 0.11 5 × 10-5
APC_P280_R -0.13 0.07 2 × 10-4 -0.10 0.05 5 × 10-4
1Wilcoxon test.
ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2Holm et al. Breast Cancer Research 2010, 12:R36
http://breast-cancer-research.com/content/12/3/R36
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Table 3: Average methylation frequency for the 196 subtype-associated CpGs
Methylation frequency (%) Number of patients P-value1
Average SD
Molecular subtype2 2 × 10-7
Basal-like 27.6 4.1 43
LumA 31.1 5.5 46
LumB 35.1 7.9 35
HER2-enriched 27.8 6.4 14
Normal-like 27.5 3.6 17
Non-classified 29.9 6.4 24
Non-GEX 34.3 8.7 10
Family status 0.007
BRCA1 29.8 7.4 15
BRCA2 36.5 8.3 13
Familial 30.3 6.6 43
Sporadic 29.9 6.0 115
ER status3 0.005
Positive 31.3 7.0 113
Negative 28.6 5.4 61
PgR status3 0.02
Positive 31.3 6.8 108
Negative 28.9 6.0 66
Histological grade 0.7
Grade 1 29.6 6.7 18
Grade 2 30.9 6.2 48
Grade 3 29.7 7.0 82
Node status 0.7
Positive 29.8 6.5 49
Negative 30.3 6.4 117
Age (years) 0.5
< 50 30.0 6.4 108
≥ 50 30.7 6.4 71
Size (mm) 0.3
≤ 20 30.6 6.4 90
> 20 28.7 6.3 76
Tissue 2 × 10-4
Normal breast 27.3 0.9 4
Tumour 30.5 6.6 189
1t-test for two categories, otherwise one-way analysis of variance. P-values < 0.05 in bold.
2P-value between subtypes basal-like, lumA, lumB, HER2-enriched and normal-like.
3Tumours with an ER or PgR content of at least 25 fmol/mg protein were considered positive for ER and PgR, respectively.
ER, oestrogen receptor; GEX, gene expression; HER2, human epidermal growth factor receptor 2; lumA, luminal A; lumB, luminal B; na, not 
available; PgR, progesterone receptor.Holm et al. Breast Cancer Research 2010, 12:R36
http://breast-cancer-research.com/content/12/3/R36
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methylated in basal-like tumours (Figure 2). Comparing
tumours based on ER status, irrespective of molecular
subtype, a higher methylation frequency was observed in
ER-positive and progesterone receptor (PgR)-positive
tumours (P  = 0.005 and P  = 0.02, respectively, t-test).
Tumours from germline BRCA2 mutation carriers had a
higher degree of CpG methylation as compared with
BRCA1-mutated, other familial and sporadic tumours (P
= 0.007, ANOVA). Additionally, the average methylation
frequency of the subtype-associated CpGs was lower in
normal breast tissue than in tumours (P = 2 × 10-4, t-test).
However, stratifying the tumours by molecular subtype,
significantly lower average methylation frequency in nor-
mal breast tissue was only found when comparing with
lumA (P  = 2 × 10-4, t-test) and lumB (P  = 2 × 10-6)
tumours, respectively.
Subtype-specific genes are often regulated by methylation
SAM analysis was performed to identify genes differen-
tially methylated for each molecular subtype. Genes that
were frequently methylated among lumB tumours were
often unmethylated among basal-like tumours, and genes
methylated in the basal-like group were more often unm-
ethylated in the lumA group [see Additional File 10]. To
investigate whether genes with subtype-specific methyla-
tion also were described as gene expression markers for
the subtypes, we utilized the gene set that Hu et al. gener-
ated to build a subtype single sample predictor (SSP) [14].
We had methylation data for 43 of the 301 SSP genes. Of
these, we found 11 to have subtype-specific methylation
patterns in our SAM analysis and in general these genes
showed expression levels that corresponded with methy-
lation status in our data set (Figure 3).
Breast cancer subtypes and polycomb-regulated genes in 
ES cells
To explore whether genes are silenced in basal-like
tumours by other mechanisms than promoter methyla-
tion, we utilized gene expression data for 286 primary
tumours classified into molecular subtypes to investigate
the expression of EZH2. We found EZH2 to be differently
expressed between subtypes (P = 1 × 10-31, ANOVA; Fig-
ure 4a). In particular, basal-like tumours displayed signifi-
cantly higher expression levels compared with the other
subtypes (P = 3 × 10-19, t-test), consistent with previous
observations [36]. Interestingly, EZH2  (located on
7q36.1) was frequently gained in basal-like tumours by
aCGH (P = 0.004, Fisher's exact test; Figure 4b), although
no case of high-level amplification was observed. To what
extent this can explain the overexpression of EZH2 in
basal-like tumours remains to be determined.
To further investigate the role of EZH2 in basal-like
tumours, we identified 225 PRC2 target genes present in
our gene expression data set by using an ES cell PRC2 tar-
get gene set identified by Lee et al. using ChIP arrays [28].
The average expression levels for these genes stratified by
molecular subtype revealed that basal-like and lumB
tumours both have low expression of genes that are tar-
Figure 2 Boxplot stratified by subtype for methylation frequen-
cies of the 196 subtype-associated CpGs. These CpGs are more fre-
quently methylated in lumB tumours and less methylated in basal-like 
tumours. P-value was calculated using analysis of variance. The num-
ber of tumours in each subtype is shown at top.
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gets of PRC2 in ES cells (P = 5 × 10-18, ANOVA; Figure
5a). For this PRC2 target gene set, we identified 134 CpG
sites, corresponding to 64 genes, for which we had meth-
ylation data. Intriguingly, basal-like tumours have low
average relative methylation levels of these CpG sites
while lumB tumours display high levels (P = 0.004, t-test;
Figure 5b). Additionally, there was a tendency towards ES
cell PRC2 target genes being more methylated than other
genes for lumB tumours, although not significant (P =
0.2, t-test), while these genes had a tendency to be less
methylated than other genes for basal-like tumours (P =
0.2, t-test; Figure 5c).
To investigate the extent to which genes with subtype-
specific expression or methylation patterns are also PRC2
targets in ES cells, we investigated three overlaps between
gene sets. First, of the 301 SSP genes with subtype-char-
acteristic expression patterns, only four genes (DUSP4,
GATA3, HOXB6 and SFRP1) were identified by Lee et al.
a s  P R C 2  t a r g e t s  i n  E S  c e l l s.  S e c o n d ,  o f  2 7  g e n e s  w i t h
strong positive correlation (correlation >0.6) to the gene
expression level of oestrogen receptor 1 (ESR1) in an
expression module for ER status developed by Desmedt
et al. [37], only three (ERBB4, FBP1 and GATA3) were
also in the ES cell PRC2 target gene set. Finally, of the 163
unique genes with methylation patterns associated with
the molecular subtypes [see Additional File 9], 15 genes
were in the PRC2 target gene set. Hence, although PRC2
targets are differentially methylated across the molecular
subtypes, it is clear that many genes with subtype-charac-
teristic expression or methylation in breast tumours are
not PRC2 targets in ES cells.
Subtypes and polycomb-regulated genes in breast cancer 
cells
To address whether genes under PRC2 control in tumour
cells corroborate our findings, we also investigated a
polycomb target gene set derived from overexpression of
the large intervening non-coding RNA (lincRNA)
HOTAIR  in the ER-negative and basal-like [19] breast
cancer cell line MDA-MB-231 [29]. Overexpression of
HOTAIR in epithelial cells leads to rearrangement of the
PRC2 binding pattern towards the one of a less differenti-
ated embryonic fibroblast, and to increased cell invasion
and metastatic potential [29]. We had expression data for
288 genes and methylation data for 50 genes (98 CpG
sites) in the MDA-MB-231 HOTAIR-PRC2 gene set.
Using this gene set, we obtained similar results as for the
ES cell PRC2 gene set (Figure 5). The relative expression
of these genes was significantly different between sub-
types (P = 1 × 10-17, ANOVA), and basal-like and lumB
tumours showed relatively low expression of these genes
(Figure 5d). High relative methylation in lumB tumours
and low in basal-like tumours were also seen for this set
of PRC2 targets (P = 1 × 10-6, t-test; Figure 5e). In this
case PRC2 target genes also had a tendency to be more
methylated than other genes in lumB tumours (P = 0.1, t-
test), while being less methylated than other genes in
basal-like tumours (P = 0.006, t-test; Figure 5f).
Figure 4 Relative gene expression levels and genomic gain of EZH2 in the different subtypes. (a) Relative expression levels of EZH2 across sub-
types. Basal-like tumours had the highest expression of EZH2. P-value was calculated using analysis of variance for all subtypes. (b) Fraction of samples 
with gain of EZH2. Gain of this gene is more frequent in basal-like tumours. P-value was calculated using Fisher's exact test between basal-like and the 
other subtypes. The number of tumours in each subtype is shown at the top.
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Figure 5 Relative expression and methylation of PRC2 target genes derived from ES and MDA-MB-231 HOTAIR cells. PRC2 targets identified 
by Lee et al. in (a to c) ES cells [28] and Gupta et al. [29] by over-expressing HOTAIR in (d to f) MDA-MB-231 cells, and present in our gene expression 
data set or methylation panel, respectively, were used. (a and d) Average relative expression levels of PRC2 target genes. Basal-like and lumB tumours 
both have low expression of these genes compared with the other subtypes. P-values were calculated using analysis of variance. (b and e) Average 
relative methylation levels of PRC2 target genes. Low methylation levels are found in basal-like tumours while lumB tumours display high levels of 
methylation of these CpG sites. P-values were calculated using t-test between basal-like and lumB tumours. (c and f) Average relative methylation 
levels for PRC2 target genes compared with other genes for basal-like and lumB tumours. P-values were calculated using t-test. The number of tu-
mours in each subtype is shown at the top.
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Finally, we addressed whether luminal breast tumours
display a distinct pattern of repressed PRC2 targets. It has
been shown that PRC2 binds to promoters in a cell-type
specific manner and can be displaced from promoters
from one set of genes, while being recruited to another
set during lineage specification [8,30]. Squazzo et al. have
shown that SUZ12 (a member of PRC2) binds to promot-
ers of glycoproteins and immunoglobulin-like proteins in
adult MCF7 breast cancer cells, whereas in embryonic
cells they bind to genes involved in transcriptional regu-
lation such as homeodomain-containing transcription
factors [30]. To investigate this issue, we used two gene
sets of polycomb targets derived from the ER-positive
and luminal [19] breast cancer cell line MCF7. For the
first gene set consisting of targets for SUZ12 [30] (hereaf-
ter called MCF7 SUZ12 targets), we had gene expression
data for 114 genes and methylation data for 20 genes (38
CpGs). For the second gene set consisting of 44 PRC2 tar-
get genes [31] (hereafter called MCF7 PRC2 targets), we
had gene expression data for 29 genes and methylation
data for 8 genes (16 CpGs). Both lumA and lumB
tumours had low relative expression of the genes in these
gene sets, while basal-like had high relative expression (P
= 1 × 10-20 and P = 3 × 10-15, ANOVA, respectively; Fig-
ures 6a and 6b). Interestingly, the genes in these two gene
sets tended to be more methylated in lumB than in lumA
tumours (Figures 6c and 6d); however, it only reached
statistical significance using the MCF7 PRC2 targets (P =
Figure 6 Relative expression and methylation of SUZ12 and PRC2 target genes derived from MCF7 breast cancer cells. (a and c) SUZ12 tar-
gets identified by Squazzo et al. [30] and (b and d) PRC2 targets identified by Tan et al. [31], and present in our gene expression data set or methylation 
panel, respectively, were used. (a and b) Average relative expression of SUZ12 and PRC2 targets, respectively. LumA and especially LumB tumours, 
have low expression of these genes. P-values were calculated using analysis of variance (ANOVA). (c and d) Average relative methylation of SUZ12 
and PRC2 targets, respectively. Higher methylation levels are found for lumB than lumA tumours. P-values were calculated using ANOVA. The number 
of tumours in each subtype is shown at top.
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0.3 and P  = 0.02, respectively, t-test). Taken together,
these results suggest that unique PRC2 occupation pat-
terns exist for the different subtypes.
Discussion
In the present study, we used an array-based technology
to investigate the methylation status of 807 selected can-
cer-related genes. By performing unsupervised clustering
of 189 breast tumours, we found that basal-like, lumA
and lumB tumours have different methylation profiles
(Figure 1). On the other hand, tumours of the normal-like
and HER2-enriched molecular subtypes did not display
distinct methylation profiles. Consistent with our methy-
lation profiling, normal-like tumours do not cluster
together based on genomic profiling either [38]. HER2-
positive tumours are in general heterogeneous with
amplification of the HER2 locus as the common denomi-
nator whereas they can be either positive or negative for
hormone receptors. Although gene expression profiling
has identified a HER2-enriched subtype, it should be
noted that HER2-positive tumours are found in all
molecular subtypes [22,39], and that expression profiles
of HER2-positive tumours are very heterogeneous [23].
Our results add support to the heterogeneous picture of
HER2-positive breast cancer, and suggest that HER2
amplification does not have a strong characteristic influ-
ence on methylation patterns.
Identification of genes with subtype-specific methyla-
tion revealed that, for example, RASSF1 and GSTP1 were
specifically methylated in lumB tumours and unmethy-
lated in basal-like tumours. These two genes have previ-
ously been shown to be significantly more methylated in
ER-positive than in ER-negative tumours [33]. Seven of
the genes significantly more methylated in one subtype
(ARHGDIB, GRB7 and SEMA3B in basal-like; MMP7 and
PEG10 in lumA; GSTP1 and CHI3L2 in lumB) have been
shown to have low expression in the corresponding sub-
type [14]. Moreover, roughly 25% of the genes used for
the expression-based SSP molecular subtype classifier
[14] and present on our assays were found in our screen
for genes with subtype-specific methylation patterns
(Figure 3). Taken together, these results suggest that
methylation plays a significant role in the different breast
tumour phenotypes.
The methylation frequency of genes with methylation
patterns associated with the molecular subtypes was sig-
nificantly higher in lumB tumours than the other sub-
types, with basal-like tumours having low methylation
frequency (Table 3). The lower degree of methylation
observed in basal-like tumours is compatible with their
unstable and aberrated genome and is possibly reflected
in a reduced transposon silencing [1]. A large difference
was also seen between tumours from BRCA1 and BRCA2
mutation carriers with tumours from BRCA2 mutation
carriers being significantly more methylated than
tumours from BRCA1  mutation carriers. This finding
emphasises the distinction between hereditary tumours.
Using 78 tumours and 11 genes Suijkerbuijk et al. [40]
found lower methylation frequencies in BRCA1-mutated
and lymph node-negative tumours than in sporadic and
lymph node-positive tumours, respectively. In our larger
set of tumours, using more than 800 genes, we could not
verify these findings (Table 3). A reason for this discrep-
ancy could be our finding of characteristic methylation
patterns for the breast cancer subtypes. As sporadic
tumours, lymph node-positive and negative tumours can
be found across all subtypes, having a large number of
tumours covering all subtypes is essential in comparisons
based on clinical variables.
We included normal breast tissue from four breast can-
cer patients to investigate the difference between methy-
lation frequencies in normal versus cancerous tissue, and
found higher frequency in the latter. This is in agreement
with previous results by Suijkerbuijk et al. [40]. However,
the variation in methylation frequency of tumours is large
due to differences between molecular subtypes. Interest-
ingly, basal-like tumours showed similar methylation fre-
quencies as the normal tissue samples, whereas luminal
tumours showed higher frequencies. It has been sug-
gested that genes having low expression in normal cells
undergo de novo methylation in tumours [10]. The high
methylation frequency in luminal tumours suggests de
novo  methylation. However, direct comparisons of
expression and methylation levels in isolated primary
luminal cells from normal tissue with levels in luminal
tumour tissue would be required to address this further.
An alternative way to epigenetically silence genes is
through histone modifications. Trimethylation of H3K27
is a known PRC2-mediated silencing mechanism essen-
tial for maintaining stem cells in an undifferentiated state
[7]. An analysis of PRC2 target gene sets derived using
both ES cells and the basal-like breast tumour cell line
MDA-MB-231 revealed low expression of these genes in
both basal-like and lumB tumours (Figures 5a and 5d).
These results are in accordance with Ben-Porath et al.
[27] who showed that targets of PRC2 in ES cells had low
to moderate expression in both basal-like and lumB
tumours. However, analysis of PRC2 targets derived using
the luminal breast tumour cell line MCF7, revealed high
expression of these genes in basal-like tumours and low
in luminal tumours (Figures 6a and 6b), suggesting
unique PRC2 target patterns for at least basal-like and
luminal tumours. These data are in accordance with
Squazzo  et al. who found that although adult tumour
cells (MCF7) and embryonic tumours both have a set of
promoters occupied by SUZ12 in common, they also have
their own unique SUZ12 occupation pattern [30].Holm et al. Breast Cancer Research 2010, 12:R36
http://breast-cancer-research.com/content/12/3/R36
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Intriguingly, basal-like tumours displayed low methyla-
tion levels of PRC2 target genes in embryonic cells
whereas lumB tumours displayed high levels (Figures 5b
and 5c). EZH2 is the core member of PRC2, which cataly-
ses the trimethylation of H3K27 [5], and we therefore
investigated the expression of this gene in breast cancer.
Indeed, we found significantly higher expression in basal-
like tumours (Figure 4a) than in the other subtypes.
Together, our results suggest that PRC2 target genes in
embryonic cells could be silenced through trimethylation
of H3K27 in basal-like tumours, whereas in lumB
tumours these genes are silenced through promoter
methylation. Moreover, polycomb proteins such as EZH2
are involved in stem cell maintenance [6], in line with
findings that basal-like breast cancer has a more stem
cell-like phenotype [21,41]. Hence, our results suggest it
would be valuable to investigate if PRC2 target genes in
embryonic cells are silenced by histone modifications in
basal-like tumours.
The reason behind the different methylation patterns in
the breast cancer subtypes is unknown but could reflect
different cellular origins or be driven by mutations in, for
example, methyltransferases. Recently, it has been sug-
gested that basal-like tumours originate from an aberrant
population of luminal progenitor cells [41]. Our results
are compatible with basal-like tumours arising in luminal
progenitors in which genes initiating a differentiated
luminal cell fate are repressed by PRC2 (Figure 7). During
normal differentiation PRC2 is displaced and these PRC2
targets are preferentially activated [42]. Our findings for
lumA tumours suggest that they arise in such a differenti-
ated luminal cell (Figure 7). Promoter methylation and
histone modifications could silence genes independently
[5]. Alternatively, polycomb-mediated methylation of
H3K27 could function as a mark of sequences for de novo
methylation of CpG islands in cancer cells [9,11,43]. In
cancer cells, PRC2 has been shown to associate with
DNMTs leading to CpG methylation [9], and therefore
more permanent repression, of PRC2 target genes. More-
over, a number of studies have shown that genes
repressed by PRC2 in ES cells are enriched among genes
becoming hypermethylated in cancer [11,34,35,43,44].
We find that our results are compatible with lumB
tumours being similar to aberrantly differentiated prolif-
erating luminal cells in which PRC2 targets are methy-
lated (Figure 7). The observed methylation of PRC2
targets is apparently not sufficient to block the differenti-
ation of these cells because lumB tumours share relatively
high expression levels of many luminal subtype-specific
markers with lumA tumours. Additionally, we found, that
some of the genes with subtype-specific expression or co-
expression with oestrogen receptor 1 (ESR1) in breast
cancer were targets of PRC2 in ES cells. An exception is
GATA3, which is a target of PRC2 in ES cells but highly
expressed in luminal tumours. During differentiation
PRC2 is relocated to other sets of target genes suggested
as a dynamic mechanism to block expression of regula-
tors of alternative cell lineages [8]. We also observed that
PRC2 targets in a luminal breast cancer cell line were
more methylated in lumB tumours, suggesting that PRC2
Figure 7 Potential model for the relations between luminal differentiation and breast cancer subtypes. PRC2-mediated gene silencing 
through trimethylation of H3K27 is common in stem/progenitor cells and would be characterised by high EZH2 expression and PRC2 targets having 
both low expression and unmethylated CpG sites. These characteristics match our findings for basal-like tumours. PRC2 is then displaced (upper path) 
and PRC2 targets are preferentially activated to promote differentiation. Such a committed cell state would be characterised by low EZH2 expression 
and PRC2 targets with both high expression and unmethylated promoters. These characteristics match our findings for lumA tumours. In cancer cells, 
an alternative route for differentiation (lower path), would be to more stably silence PRC2 target genes by promoter methylation. PRC2 associates with 
DNA methyltransferases (DNMTs) leading to hypermethylation of PRC2 targets. Such a committed cell state would be characterised by low EZH2 ex-
pression and PRC2 targets with both low expression and hypermethylated CpG sites. These characteristics match our findings for lumB tumours.
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targets may become methylated also later in the differen-
tiation of lumB tumours. In addition, overexpression of
EZH2 in basal-like tumours could methylate non-histone
targets [45] potentially adding further differences
between basal-like and lumB tumours.
Somatic mutations in both EZH2 and the H3K27 dem-
ethylase gene KDM6A (UTX) have been found in human
cancer [46,47]. It may be that somatic alterations in his-
tone methyltransferases contribute to the different meth-
ylation patterns for the breast cancer subtypes. For
example,  EZH2  mutations have been found to be fre-
quent in large B-cell lymphomas of germinal-cell origin
and suggested to underlie the enhanced methylation at
PRC2 targets that have been observed in this cancer type
[34,46]. It would be interesting to investigate the muta-
tion status of methyltransferases across molecular sub-
types of breast cancer to, for example, explore if
methylation of PRC2 targets and the general high degree
of methylation in lumB tumours are associated with
mutations in such genes. Although Kondo et al. found
that DNA methylation and H3K27me3 in general do not
target the same genes in cancer cell lines, they observed
high DNA methylation at H3K27me3 targets in the colon
cancer cell line SW48 [5]. Interestingly, SW48 is affected
by the CpG island methylator phenotype in which many
genes are silenced by methylation [48], similar to our
findings for lumB tumours. We have used PRC2 targets in
ES and breast cancer cells, and future studies will be
needed to address whether PRC2 targets in luminal pro-
genitor or ER-negative cells from normal breast tissue are
methylated in lumB tumours. Nevertheless, it should be
noted that a significant subset of the genes identified as
polycomb targets in ES cells are also targets in breast can-
cer cells [29]. Moreover, it would be valuable to deter-
mine if the selected set of CpGs analysed in this study
mirrors a more global promoter methylation pattern.
Conclusions
Using an array-based platform with more than 800 can-
cer-related genes we have revealed that the molecular
subtypes, especially basal-like, lumA and lumB tumours,
harbour specific methylation profiles. Our data add a
novel layer of information to the differences between the
molecular subtypes and the heterogeneous nature of
breast cancer.
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